Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 644 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lacrimal Apparatus Diseases Clear all
Completed Phase 2 Interventional

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

NCT07264517
View directory record Official record
Conditions
Dry Eye Disease
Interventions
GRF312 5%, Placebo Comparator
Drug · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Glendale, California • Grove, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 25, 2026, 12:23 PM EDT
Completed Phase 3 Interventional

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

NCT00025818
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic
Interventions
Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Waterbury, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 25, 2026, 12:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Applications of Advanced Ophthalmic Imaging

NCT03135327
View directory record Official record
Conditions
Multiple Sclerosis, Dry Eye Syndromes, Diabetic Retinopathy, Presbyopia, Myopia, Dementia
Interventions
Ocufolin
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 25, 2026, 12:23 PM EDT
Not listed Phase 4 Interventional

Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing FLACS With Premium IOL

NCT04863742
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
Drug
Lead sponsor
Sight Medical Doctors PLLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Brentwood, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 25, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction

NCT00755183
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
testosterone ophthalmic solution, vehicle of testosterone ophthalmic solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 25, 2026, 12:23 PM EDT
Terminated Not applicable Interventional Results available

Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in Dry Eye Disease

NCT03827564
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Intranasal Tear Neurostimulator (ITN) [TrueTear®]
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 25, 2026, 12:23 PM EDT
Not listed Not applicable Interventional

Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy

NCT01586767
View directory record Official record
Conditions
Adenoid Cystic Carcinoma, Squamous Cell Carcinoma, Sinonasal Carcinoma, Sinonasal Undifferentiated Carcinoma, Mucoepidermoid Carcinoma, Schneiderian Carcinoma, Myoepithelial Carcinoma, Esthesioneuroblastoma, Melanoma
Interventions
Proton radiation therapy, Intensity-modulated radiotherapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 25, 2026, 12:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Extended Tear Film Break Up Time (TFBUT) With an Ocular Emulsion

NCT01368198
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Balance Lubricating Eye Drops, OPTIVE™
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 25, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

NCT03879863
View directory record Official record
Conditions
Dry Eye
Interventions
Reproxalap Ophthalmic Solution (0.25%) QID, Vehicle Ophthalmic Solution QID, Reproxalap Ophthalmic Solution (0.25%) QID to BID, Vehicle Ophthalmic Solution QID to BID
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 25, 2026, 12:23 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Clinical Trial for CTD-ILD Treatment

NCT01424033
View directory record Official record
Conditions
Interstitial Lung Disease, Connective Tissue Disease
Interventions
N-Acetylcysteine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 25, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)

NCT05133180
View directory record Official record
Conditions
Dry Eye
Interventions
Oxervate, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Glendale, California • Newport Beach, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 25, 2026, 12:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

NCT04496960
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
tofacitinib, Placebo
Drug · Other
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 25, 2026, 12:23 PM EDT
Completed Phase 1 Interventional

Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT02242032
View directory record Official record
Conditions
Dry Eye Disease
Interventions
P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 25, 2026, 12:23 PM EDT
Completed Not applicable Interventional Results available

Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator

NCT02798289
View directory record Official record
Conditions
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions
Oculeve Intranasal Neurostimulator
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Artesia, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 25, 2026, 12:23 PM EDT
Completed Phase 4 Interventional

Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

NCT05514041
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Varenicline solution, Placebo nasal spray (OC-01 Vehicle Nasal Spray)
Drug
Lead sponsor
Stephenson Eye Associates
Other
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Venice, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 25, 2026, 12:23 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine

NCT06329661
View directory record Official record
Conditions
Dry Eye Disease, Endothelial Cell
Interventions
Cyclosporine ophthalmic solution, 0.1%, Saline solution, 0.6%
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Newport Beach, California • Torrance, California • Garner, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 12:23 PM EDT
Completed Not applicable Interventional

Tear Lipid Layer Thickness Assessments With Perfluorohexyloctane Eye Drops

NCT05288582
View directory record Official record
Conditions
Dry Eye
Interventions
NovaTears
Device
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 25, 2026, 12:23 PM EDT
Recruiting Phase 2 Interventional

Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye

NCT07413172
View directory record Official record
Conditions
Dry Eye, Eye Diseases, Eyes Dry Chronic
Interventions
Autologous Serum Tears (50% Autologous Serum Tears + 0.2% Sodium Hyaluronate), Biological - Autologous Serum Tears (50% Autologous Serum Tears + Balanced Saline Solution (BSS), Standard of Care (SOC) Treatment
Biological · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 25, 2026, 12:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye

NCT02420730
View directory record Official record
Conditions
Healthy Volunteers, Dry Eye Syndromes
Interventions
AGN-232411, AGN-232411 Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Artesia, California • Glendale, California • Montebello, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 25, 2026, 12:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diurnal Variation of Tear Meniscus and Tear Osmolarity

NCT01206244
View directory record Official record
Conditions
Dry Eye
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Oct 25, 2026, 12:23 PM EDT
Completed Phase 2 Interventional

Etanercept Therapy for Sjogren's Syndrome

NCT00001954
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 12:23 PM EDT
Not listed Phase 2 Interventional

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

NCT06225973
View directory record Official record
Conditions
Dry Eye Disease
Interventions
TL-925, Placebo
Drug · Other
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
18
States / cities
Phoenix, Arizona • Glendale, California • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 25, 2026, 12:23 PM EDT
Completed No phase listed Observational

An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

NCT06439394
View directory record Official record
Conditions
Dry Eye
Interventions
Optive MEGA-3 (OM3)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 25, 2026, 12:23 PM EDT
Completed Not applicable Interventional Results available

Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery

NCT01808560
View directory record Official record
Conditions
Blepharitis, Dry Eye Syndrome
Interventions
LipiFlow Pre-Treatment, LipiFlow Post-treatment
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Hoffman Estates, Illinois • Lake Villa, Illinois • Winchester, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 25, 2026, 12:23 PM EDT